Novozymes Korea Ltd. - Industrial Enzymes, Microorganisms | FOOD INGREDIENTS CHINA 2025
Exhibiting at FOOD INGREDIENTS CHINA 2025
NECC (Shanghai)
17 Mar - 19 Mar, 2025
Product Offerings
Product Categories:
Microorganisms, Food Additives and Ingredients, Functional and Nutraceutical Foods, Food Cultures & Enzymes, Biotechnology, Industrial Enzymes, Information Technology and Software, Consulting and Professional Services, Probiotics, Agricultural Machinery and Equipment, Food Processing Machines and Equipment, Feed and Feed Additives, Agricultural Solutions, Biosolutions, Food Additives & Ingredients, IT & Software
Functional Proteins: Specialty Proteins for Food and Feed
Product Categories
Microorganisms
Food Additives and Ingredients
Functional and Nutraceutical Foods
Food Cultures & Enzymes
Biotechnology
Industrial Enzymes
Information Technology and Software
Consulting and Professional Services
Probiotics
Agricultural Machinery and Equipment
Food Processing Machines and Equipment
Feed and Feed Additives
Agricultural Solutions
Biosolutions
Food Additives & Ingredients
IT & Software
Available Products
Detergent Enzymes
Food Enzymes
Biofuel Enzymes
Probiotics
Agricultural Microbials
Specialty Proteins for Food and Feed
Novonesis (诺和新元), officially operating in China as 诺维信（中国）投资有限公司, is a global biosolutions leader formed from the merger of two biotechnology giants: Novozymes and Chr. Hansen. Headquartered globally in Denmark and with significant operations in China, Novonesis integrates cutting-edge biotechnology to drive innovation in food production, agriculture, healthcare, and industrial applications. The company is committed to unlocking the power of biology to transform industries and enable a healthier, more sustainable world.
Company Overview
Novonesis was officially launched in January 2024 as the unified brand following the merger of Novozymes A/S and Chr. Hansen Holding A/S. The merger created one of the world’s most advanced biosolutions companies with operations in over 30 countries and a strong manufacturing and R&D footprint in China. In China, the company operates as 诺维信（中国）投资有限公司, with its main office in Beijing.
Global and China Market Presence
Employees Worldwide: Over 10,000
China Headquarters: Beijing
China R&D and Production Sites: Tianjin, Wuxi, and Beijing
Global Revenue (2023): Estimated at €3.5 billion pre-merger
China Revenue Share: Approx. 15–20% of global revenue (industry estimate)
China is one of Novonesis' most important strategic markets, contributing significantly to revenue and innovation activities, especially in the food and beverage, textiles, and agricultural biotechnology sectors.
Core Business Segments
Novonesis operates across three main pillars:
Food & Health Biosolutions
Dairy cultures and probiotics
Baking enzymes
Brewing and wine enzymes
Fermented plant-based ingredients
Human and animal probiotics
Agriculture & Industrial Biosolutions
Microbial inoculants for crops
Biological pest and disease control
Enzymes for textile and detergent industries
Bioethanol enzymes
Biopharma and Diagnostics
Enzymes for molecular diagnostics
Biopharmaceutical fermentation components
Enzyme systems for nucleic acid purification and PCR
The company's offerings cater to diverse industries including food processing, agriculture, household care, biopharma, and energy.
Innovation and R&D
Novonesis is an R&D powerhouse, investing approximately 13% of annual revenue in research and innovation.
Global R&D Spend (2022, pre-merger): €460 million
R&D Employees: Over 1,500 globally
China Innovation Centers: Located in Beijing and Wuxi, focusing on local market adaptation and fermentation optimization
IP Portfolio: Over 7,000 active patents globally
Novonesis' focus on synthetic biology, enzyme engineering, and microbial fermentation positions it as a global innovation leader.
Certifications and Compliance
Novonesis operates under the highest global regulatory and quality standards, including:
ISO 9001: Quality Management
ISO 14001: Environmental Management
FSSC 22000: Food Safety Certification
GMP: For biopharmaceutical ingredients
Non-GMO, Kosher, and Halal certifications across multiple product lines
In China, the company complies with all CFDA and SAMR regulatory frameworks for food additives, feed additives, and industrial biosolutions.
Sustainability Commitments
As a purpose-driven biosolutions company, Novonesis prioritizes sustainable growth:
Carbon Reduction: Targets 75% reduction in absolute CO₂ emissions by 2030
Science-Based Targets Initiative (SBTi) Approved
Circular Economy: Over 80% of product portfolio enables customers to reduce waste, water use, or emissions
China Green Factory: Tianjin plant recognized for energy efficiency and emissions reduction
Strategic Clients and Applications
Novonesis supplies biosolutions to major clients in:
Food and Beverage: Yili, Mengniu, COFCO, Wahaha, Nestlé
AgTech: Major seed and crop protection firms
Biopharma: Global biotech firms and local Chinese diagnostic companies
Detergents and Home Care: International FMCG companies and local OEM manufacturers
Its enzymes and microbial solutions improve yield, shelf life, nutritional profile, and sustainability across value chains.
M&A and Strategic Expansion
The creation of Novonesis marked one of the largest biotech mergers in history, valued at over €12.3 billion. This consolidation brought together:
Novozymes: The global leader in industrial enzymes and microbes
Chr. Hansen: The leader in dairy cultures and food probiotics
This integration provides expanded biosolution synergies, greater innovation potential, and a broader global footprint, including deeper localization in China.
Recognition and Industry Leadership
Top 10 Biotech Employers Globally – Science Magazine
Ranked #1 in Enzyme Production Worldwide
Recognized as a Sustainability Leader in Dow Jones Sustainability Index
IFBA Member (International Food & Beverage Alliance)
Conclusion
Novonesis represents the future of biology-driven innovation. With a robust presence in China through 诺维信（中国）投资有限公司, it serves as a key enabler for healthier foods, sustainable farming, cleaner industrial processes, and advanced healthcare. By combining scientific expertise with scalable solutions, Novonesis is redefining the role of biotechnology in global development.
